Drug repurposing: Promises of edaravone target drug in traumatic brain injury
Loading...
Files
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Bentham Science Publishers
Abstract
Edaravone is a potent free-radical scavenger that has been in the market for more than 30 years. It was originally developed in Japan to treat strokes and has been used there since 2001. Aside from its anti-oxidative effects, edaravone demonstrated beneficial effects on pro-inflammatory responses, nitric oxide production, and apoptotic cell death. Interestingly, edaravone has shown neuroprotective effects in several animal models of diseases other than stroke. In particular, edaravone administration was found to be effective in halting amyotrophic lateral sclerosis (ALS) progression during the early stages. Accordingly, after its success in Phase III clinical studies, edaravone has been approved by the FDA as a treatment for ALS patients. Considering its promises in neurological disorders and its safety in patients, edaravone is a drug of interest that can be repurposed for traumatic brain injury (TBI) treatment. Drug repurposing is a novel approach in drug development that identifies drugs for purposes other than their original indication. This review presents the biochemical properties of edaravone along with its effects on several neurological disorders in the hope that it can be adopted for treating TBI patients. © 2021 Bentham Science Publishers.
Description
Keywords
Amyotrophic lateral sclerosis, Drug repurposing, Edaravone, Neurological disorders, Stroke, Traumatic brain injury (tbi), Animals, Brain injuries, traumatic, Drug repositioning, Free radical scavengers, Humans, Neuroprotective agents, Pharmaceutical preparations, 3 nitrotyrosine, Acetylsalicylic acid, Adenosine triphosphate, Atorvastatin, Cytokine, Endothelial nitric oxide synthase, Low density lipoprotein, Nitric oxide, Norphenazone, Oxidized low density lipoprotein, Ozagrel, Reactive oxygen metabolite, Vasculotropin, Drug, Neuroprotective agent, Scavenger, Apoptosis, Behavior, Blood brain barrier, Blood vessel permeability, Brain concussion, Brain edema, Brain infarction, Brain infarction size, Brain vasospasm, Cerebrovascular accident, Cognitive defect, Depression, Disease duration, Dna damage, Dose response, Drug approval, Drug cost, Drug efficacy, Drug formulation, Drug indication, Drug marketing, Drug mechanism, Drug safety, Food and drug administration, Forced swim test, Human, Immune response, Inflammation, Ischemic stroke, Japan, Lipid peroxidation, Loading drug dose, National institutes of health stroke scale, Neurologic disease, Neuroprotection, Nonhuman, Oxidative stress, Pathophysiology, Phase 1 clinical trial (topic), Phase 2 clinical trial (topic), Phase 3 clinical trial (topic), Phase 4 clinical trial (topic), Randomized controlled trial (topic), Review, Stem cell, Stroke patient, Traumatic brain injury, Treatment outcome, United states, X-ray computed tomography, Animal